Gimme Care vs Hers
Gimme Care costs $69 less a month, and both sell semaglutide and tirzepatide.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Gimme Care
Best for: semaglutide at $130/month, 39% below the typical price
Visit Gimme Care →
Hers
Best for: coverage in all 50 states, which most sellers will not confirm
Visit Hers →If you are choosing between Gimme Care and Hers, the first difference is cost: Gimme Care is $69 a month cheaper at the entry price. Both prescribe semaglutide and tirzepatide, so moving from one to the other would not change your drug. Gimme Care leads our six-part score, 8.7 to 7.0.
Gimme Care vs Hers price
Gimme Care is the cheaper way in: $130 a month against $199 a month at Hers. That is $69 less each month (35% lower), or about $828 over a year of treatment.
Drug by drug: Semaglutide is cheaper at Gimme Care ($130 a month vs $199 a month); tirzepatide is cheaper at Gimme Care ($163 a month vs $299 a month).
Medications and formats
Both sell semaglutide and tirzepatide.
On format, Gimme Care prices compounded injections, while Hers prices compounded injections and brand-name pens.
If you want the FDA-approved brand rather than a compounded version, Hers is the only one of the two with a brand-name price.
Where each one treats patients
Gimme Care lists 51 states, and Hers lists 50 states.
They overlap in 50 states. Gimme Care alone covers District of Columbia.
Pricing
Gimme Care
Hers
Brand Zepbound from $299/mo medication-only; requires Hers Weight Loss Membership ($149/mo)
What each price covers
Both prices cover the medication itself.
Gimme Care's price also covers the clinician visit and shipping, which Hers does not claim.
Gimme Care is silent on lab work and coaching.
Hers is silent on shipping and lab work.
Gimme Care
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Hers
Covered by the monthly price
Medication
In the price
Clinician visits
Charged on top
Shipping
Not stated
Lab work
Not stated
Coaching
Charged on top
Where each one scores higher
Overall, Gimme Care scores 8.7 and Hers 7.0 out of 10.
Gimme Care is stronger on value (8.1 vs 3.0) and support (7.0 vs 3.0).
Effectiveness, user experience, trust & safety and accessibility are within half a point.
Gimme Care
8.7/10
Hers
7.0/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
Neither Gimme Care nor Hers has an FDA warning letter on record with us.
Features & Coverage
| Feature | Gimme Care | Hers |
|---|---|---|
| Starting Price | ✓$130/mo | $199/mo |
| Features | ✓5 features | 2 features |
| States Available | ✓51 | 50 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warning Letters | None | None |
About Gimme Care
Gimme Care sells compounded semaglutide at $130-$160/mo and compounded tirzepatide at $163-$199/mo, microdose options included. It is LegitScript verified, available in all 50 states plus DC, with no membership fees.
Read our full Gimme Care review →About Hers
Hers is the women-focused telehealth brand from Hims and Hers. It sells compounded semaglutide on a 6-month plan.
Read our full Hers review →Pros & Cons
Gimme Care
What we like
- Semaglutide costs $130 a month, 29% below the $184 median for compounded semaglutide across the sellers we compare
- Tirzepatide costs $163 a month, 35% below the $250 median for compounded tirzepatide across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price stays the same as your dose goes up
- The monthly price includes the medication, clinician visits and shipping
- Serves all 50 states
- We found no FDA warning letters issued to Gimme Care
Watch-outs
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Hers
What we like
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication
- Serves all 50 states
- We found no FDA warning letters issued to Hers
Watch-outs
- Not included in the monthly price: clinician visits, coaching
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
Gimme Care wins this one, 8.7 to 7.0, above all for semaglutide at $130/month, 39% below the typical price. It also costs $69 less each month than Hers. Hers fits better if coverage in all 50 states, which most sellers will not confirm is your priority.
Choose Gimme Care if…
You want semaglutide at $130/month, 39% below the typical price and an opening price near $130 a month.
Choose Hers if…
You want coverage in all 50 states, which most sellers will not confirm and an opening price near $199 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
HealthRX
Compounded semaglutide at $133/month
From $133/mo
Get started →RNK Health
An oral route if you will not self-inject
From $197/mo
Get started →He & She MD
Starting below a standard dose, with microdose tiers
From $99/mo
Get started →Gimme Care vs Hers: FAQ
Close alternatives to Gimme Care and Hers
- Gimme Care vs Bioverse
- Gimme Care vs Alternate Health Club
- Gimme Care vs DoctorAdam
- Gimme Care vs Longevixx
- Hers vs Hims
- Hers vs Noom
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.